Objective: To investigate whether blood-brain barrier (BBB) permeability, as measured by dynamic contrastenhanced magnetic resonance imaging (DCE-MRI), can provide early detection of suboptimal treatment response in relapsing-remitting multiple sclerosis (RRMS). Methods: Thirty-five RRMS patients starting on fingolimod or natalizumab, drugs with a common effect of decreasing lymphocyte influx into the central nervous system, were scanned with DCE-MRI at 3T prior to treatment and at 3 and 6 months posttreatment. We calculated the influx constant K i , a measure of BBB permeability, using the Patlak model. Suboptimal treatment response was defined as loss of no evidence of disease activity (NEDA) status after 2 years of treatment. Results: Subjects with loss of NEDA status at 2 years had a 51% higher mean K i in normal-appearing white matter (NAWM) measured after 6 months of treatment, compared to subjects with maintained NEDA status (mean difference 5 0.06ml/100g/min, 95% confidence interval [CI] 5 0.02-0.09, p 5 0.002). K i in NAWM at 6 months was a good predictor of loss of NEDA status at 2 years (area under the curve 5 0.84, 95% CI 5 0.70-0.99, p 5 0.003), and a value above 0.136ml/100/g/min yielded an odds ratio of 12.4 for suboptimal treatment response at 2 years, with a sensitivity of 73% and a specificity of 82%. Interpretation: Our results suggest that BBB permeability as measured by DCE-MRI reliably predicts suboptimal treatment response and is a surrogate marker of the state of health of the BBB. We find a predictive threshold for disease activity, which is remarkably identical in clinically isolated syndrome as previously reported and established RRMS as investigated here.
the endothelium, thereby directly suppressing lymphocyte passage across the blood-brain barrier (BBB). 2 Fingolimod is an agonist of the sphingosine-1 receptor, inducing receptor internalization and thereby trapping encephalitogenic lymphocytes in lymph nodes, 3 preventing them from migrating into the central nervous system. Hence, although the mechanism of action of these two drugs is different, their final effect is the same, that is, a reduction of the absolute number of lymphocytes trafficking across the BBB, as demonstrated by an equivalent reduction in CD4 lymphocyte counts in the cerebrospinal fluid (CSF). 4 Both treatments have been shown to be highly efficacious in reducing relapse rates by 54 to 68%, reducing occurrence of new T2 lesions on MRI as well as the number of visibly contrastenhancing lesions. [5] [6] [7] Despite the high overall efficacy, the treatment response is highly heterogeneous, and a subset of patients still experience disease activity. 8 To evaluate treatment response, the concept of no evidence of disease activity (NEDA), which uses a zero-tolerance threshold (no signs of disease activity in any of 3 domains) has been proposed as a treatment goal. [9] [10] [11] Evaluating NEDA status after 2 years of DMT may be a reasonable approach, because it holds a positive predictive value of 78.3% for no progression at 7 years, with only minor improvement for re-evaluation at years 3 to 5. 11 However, early detection of suboptimal treatment response is becoming increasingly important, both in the context of the increasing number of available therapies 5, 12, 13 and due to DMTs seeming to have their best effect in the early stages of disease, 14 but no current method or clinical variable exists that is able to perform such stratification. 8, 15 We have previously reported that BBB permeability in multiple sclerosis (MS) normal-appearing white matter (NAWM), measured as the influx constant K i by dynamiccontrast enhanced MRI (DCE-MRI), is abnormal when compared to controls, is a marker of recent clinical relapse activity, and is attenuated by disease-modifying treatment. 16 K i in NAWM correlates with biomarkers of immune cell trafficking in the CSF, and predicts conversion from optic neuritis to MS 2 years after onset. 17 Hence, we hypothesize that K i can stratify MS patients according to DMT response, here defined as loss of NEDA status at 1 and 2 years of second-line treatment. Furthermore, we aim to characterize the mechanistic relationship between K i and cellular traffic, in the setting of treatments whose common end result is a reduction in lymphocyte traffic across the BBB.
Patients and Methods

Study Participants
We prospectively included all RRMS patients referred for MRI by the MS clinic at Rigshospitalet, Glostrup between August 2011 and November 2013 as part of an evaluation prior to initiation of natalizumab or fingolimod treatment. Inclusion criteria were: (1) an established diagnosis of MS, (2) clinical indication for treatment with either natalizumab or fingolimod, and (3) age 5 18 to 59 years. Exclusion criteria were: (1) other concurring disease and (2) contraindication to MRI scan or MRI contrast agent. Eighty-five RRMS patients were assessed for eligibility, of whom 45 patients met the inclusion criteria and agreed to participate in a baseline scan (Fig 1) . Thirty-five of these proceeded to initiation of either natalizumab or fingolimod, all of whom had a follow-up MRI performed at 3 months posttreatment. Twenty-nine patients participated in the 6-month posttreatment MRI. After study completion, 2 subjects were excluded, the first due to the occurrence of antinatalizumab antibodies, which resulted in treatment cessation after 5 months of treatment, and the second due to suspected side effects to fingolimod in the form of macular edema, which resulted in treatment cessation after 8 months. Follow-up MRI scans were performed as close as possible to the 3-month (mean 5 97 days, standard deviation [SD] 5 13 days) and 6-month time points (mean 5 189 days, SD 5 17 days) posttreatment using the therapy initiation day as reference and consisted of axial T2, axial fluid-attenuated inversion recovery (FLAIR), and axial postcontrast T1 of the cerebrum as well as DCE-MRI (see below for sequence parameters). Spinal cord assessment was performed at baseline, but not at the 3-and 6-month followup scans. We recorded any use of methylprednisolone during the course of the study, with the intention to postpone any 3-or 6-month follow-up scan by 2 months after completion of steroid treatment. Only 1 subject was treated with intravenous methylprednisolone during the first 6 months of the study. This occurred 4 months after treatment initiation, due to a major relapse 65 days before the planned 6-month scan, obviating the need for postponing the scan. Clinical data were obtained from hospital records 2 years after second-line treatment initiation for each individual subject. Collected variables were: baseline MS disease duration, baseline treatment status, history of methylprednisolone use, clinical relapses 12 months prior to second-line treatment initiation, and number of relapses, MRI activity, and Expanded Disability Status Scale (EDSS) at 1 and 2 years after treatment initiation. All subjects had regular clinical follow-up visits 3, 6, 12, 18, and 24 months posttreatment as part of standard clinical practice. Antinatalizumab antibodies were measured at 3, 6, 9, and 12 months. Collection of clinical data was performed by an experienced MS clinician who was blinded to the DCE-MRI results (another researcher analyzed the MRI data). Subjects who missed a clinical visit or an MRI were treated as missing data for the purpose of statistical analysis. Only subjects who completed a full 1 or 2 years of treatment were included in the 1-and 2-year analyses.
Outcome Measures
We used the following definitions. Relapse was defined as the appearance of new neurological symptoms or signs that lasted >24 hours in the absence of concurrent fever or illness. 18 The treating physician recorded relapses at the face-to-face visits at 3, 6, 12, 18, and 24 months. Progression was defined as an EDSS score increase of 1 or more points recorded at a biannual clinical visit that was sustained at the subsequent clinical visit 6 months later. 11, 19 If the EDSS score was zero at baseline, progression was defined as an EDSS score change of 1.5 or more that was sustained at the subsequent clinical visit. 11 MRI activity was defined as new or enlarging T2 hyperintense lesions or T1 gadolinium-enhancing lesions in brain or spinal cord. To qualify as no evidence of MRI activity, new T2 hyperintense lesions and T1 gadolinium-enhancing lesions had to be absent on brain and spinal cord MRI. As recently suggested, disease activity occurring within the first 3 months after initiation of natalizumab or fingolimod treatment was disregarded when assessing NEDA status, to allow for development of a full treatment effect. 10, 20 The earliest occurring loss of NEDA events within the 3 NEDA subdomains were (1) a new T 2 lesion at 6 months (this subject had another new T 2 lesion at 1 year thus also fulfilling loss of NEDA at 12 months), (2) a relapse at 7 months, and (3) an EDSS increase at 1 year. Thus, loss of NEDA status did not occur prior to the 6-month MRI scan. , 5 slices, slice thickness 5 8mm. Data for an initial measurement of relaxation time (T1) and equilibrium magnetization (M0) were generated using a series of saturation time delays from 120 milliseconds to 10 seconds, covering the same slices as imaged during the bolus passage. The dynamic sequence used a saturation time delay of 120 milliseconds, giving a time resolution of 1.25 seconds, and 750 time points, corresponding to a total sampling duration of 15.7 minutes. The automatic bolus injection (Spectris; MedRad, Warrendale, PA) with speed 3ml/s followed by 20ml saline was started after the 10th time point. The dose of contrast agent (gadobutrol 1mmol/ml) was 0.045mmol/kg body weight. We acquired a separate slice at the level of the internal carotid artery to obtain an arterial input function with minimal partial volume for every subject. The remaining 4 DCE slices were used for defining regions of interest (ROIs) and subsequent estimation of tissue pharmacokinetic values. To achieve a full clinical dose of gadobutrol (0.1ml/kg), which is important for adequate detection of visibly contrast-enhancing lesions, 21 we injected the remaining contrast agent after the DCE acquisition and waited 5 minutes before acquiring the postcontrast T1 sequence.
Ethics
MRI Sequences and ROIs
We used an axial T2-weighted MRI sequence (5 slices, echo time 5 100 milliseconds, repetition time 5 3,000 milliseconds, acquired voxel size 5 0.57 3 0.76 3 8mm ) with same orientation and slice thickness (8mm) as our DCE-MRI sequence, to manually draw ROIs in the periventricular NAWM, and in the normal-appearing thalamic gray matter in both hemispheres, avoiding inclusion of, or proximity to, any MS lesions or diffusely abnormal white matter, as previously described in detail. 16 include the nearest 30mm of nonenhancing tissue. Our 4 DCE slices were placed with exactly the same angulation and anatomical position as the previous scan (evaluated for every scan). We ensured consistent positioning and size of our ROIs across different study time points by visual alignment with the previous scan.
Permeability Estimation
The DCE-MRI data were analyzed with a semiautomated procedure 22 using in-house MATLAB-based software. The DCE time series was converted to units of contrast agent concentration using T1 and M0, as determined from the multiple saturation delay data, and a contrast agent relaxivity of 4s 21 / mM
21
. The input function was measured in the voxel of the internal carotid artery with maximal signal change during the bolus passage and was corrected for partial volume by normalizing to a magnitude-and phase-derived venous outflow function, sampled in the sagittal sinus 23 ad modum Van Osch. 24 The median signal-time curve for all voxels in the ROI was extracted and used to calculate permeability. For each tissue type, we used the median value of permeability to exclude effects of possible outliers (eg, 4 regions of NAWM were drawn, of which the median was used to represent NAWM). Every subject was represented by 1 value calculated as a mean of the tissue-specific ROIs, as previously described. 16, 17, 25 Tissue concentration-time curves were evaluated using a combination of model-free deconvolution and a Patlak model, as described in previous work. 26 Permeability values, measured as Table 1 . Three subjects experienced a relapse shortly after starting treatment (7, 8 , and 20 days after treatment initiation), but per protocol these were disregarded. Subjects who lost NEDA status at 2 years had a 51% higher K i in NAWM at 6 months posttreatment (mean difference 5 0.06 ml/100g/min, 95% CI 5 0.02-0.09, p 5 0.002) and a 78% higher annual relapse rate (ARR) 1 year pretreatment (mean difference 5 0.93, 95% CI 5 0.38-1.5, p 5 0.002; all Student t tests), when compared to subjects who maintained NEDA status (see Table 1 and Fig 5) . An ROC curve with loss of NEDA at 2 years as outcome showed that K i in NAWM at 6 months was a good predictor of loss of NEDA status at 2 years, with an AUC of 0.84 (95% CI 5 0.70-0.99, p 5 0.003; Fig 6) . The optimal threshold, defined as the value that provided the highest Table 2) . Two subjects switched to other therapies after 5 and 8 months, possibly influencing the NEDA outcome at 2 years. These were included in the primary analysis if they were on treatment while K i was measured. Excluding these 2 subjects from the ROC curve analysis of K i in NAWM at 6 months, with NEDA at 2 years as outcome, only caused minor changes to the results (AUC 5 0.84, 95% CI 5 0.70-0.99, p 5 0.003, sensitivity 73%, specificity 81%).
DCE-MRI versus Conventional Contrast Imaging
Ten of 35 subjects (29%) had 1 or more contrastenhancing lesions on baseline MRI, and although these subjects had higher mean values of K i at baseline (NAWM, 0.15ml/100g/min; thalami, 0.15ml/100g/min), the difference was not significant when compared to subjects without contrast-enhancing lesions (NAWM, 0.14ml/100g/ min; thalami, 0.14 ml/100g/min; mean difference: NAWM, 0.01ml/100g/min, 95% CI 5 -0.05 to 0.07; thalamus, 0.01ml/100g/min, 95% CI 5 20.03 to 0.05). Only 2 subjects had contrast-enhancing lesions on the 3-month follow-up MRI, and no subjects showed contrast enhancement at the 6-month follow-up. We found no correlation between gadolinium-enhancing lesions at baseline and permeability at baseline, 3 months, or 6 months.
Discussion
Mechanistic Insights
This study enables investigation of the mechanistic relationship between K i (as measured by DCE-MRI) and cellular trafficking, by manipulation with diseasemodifying treatments, which decrease cellular traffic across the BBB. We have previously found a correlation between K i and cellular traffic into the CSF, and absence of correlation between K i and albumin quotient, perhaps suggesting that K i may be a surrogate marker of cellular influx. 17 This study addresses this issue, because the subjects maintaining NEDA represent an experimental situation where cellular traffic has been inhibited pharmacologically. We observe an apparent delay in the effect on K i such that 6-month but not 3-month K i predicted NEDA after 2 years. This lag is suggestive of an indirect process as opposed to an immediate effect of decreased cellular influx on K i -which could reflect healing of the BBB solute barrier in the first 3 months after initiation of treatment. In those losing NEDA, one can hypothesize ongoing damage to the BBB. Hence, the association between cellular traffic and K i may not be direct, but more likely represents a sequence of events where changes in cellular influx predate changes in the physical integrity of the BBB solute barrier. Hence, solute BBB permeability appears to be a prognostic marker, by reflecting the "state of health" of the BBB. This study illustrates, in vivo, the fundamental difference between cellular and solute traffic in man. Dissociation between cellular traffic and solute permeability has been observed in vitro, where interferon beta reduces lymphocyte transmigration, while having no effect on the permeability to albumin. 35 We have previously reported that a K i > 0.13ml/ 100g/min identifies optic neuritis subjects with high risk of conversion to RRMS, adding significant value Presence of visibly contrast-enhancing lesions was not a significant determinant of K i in NAWM or thalamus at baseline, 3 months, or 6 months. Furthermore, K i in NAWM and thalamus was highly correlated in the same subjects at baseline (Spearman CC 5 0.86), 3 months (CC 5 0.88), and 6 months (CC 5 0.82). Thus, the predictive effect of K i is unlikely to be a carryover from the prognostic effect of contrast-enhancing lesions or a result of spillover of contrast agent from enhancing lesions into the surrounding NAWM. Assuming a textbook value of water diffusion in brain tissue of 1.0 3 10 29 m 2 /s, 37 the distance a water molecule that has been in contact with contrast agent can diffuse during our DCE acquisition of 15 minutes is 10 29 m 2 /15 3 60 5 0.95mm. Thus, it is highly unlikely that water from a gadolinium-enhancing lesion would diffuse into our NAWM ROIs. However, one study found contrast-enhancing lesions in the first year of natalizumab treatment to predict future disease progression. 38 In our cohort, contrast-enhancing lesions were only seen in 2 subjects at 3 months and none was observed at 6 months or at 1 year. Despite this, K i at 6 months predicted NEDA at 2 years. This highlights the value of DCE-MRI in the detection of diffuse low-level BBB leakage, as distinct from the focal high-level leakage detected by conventional contrast MRI, most likely reflecting the different pathological processes in MS lesions and NAWM. The acute MS lesion is characterized by demyelination, axonal damage, gliosis, lymphocyte and macrophage infiltrates, and focal BBB damage, whereas NAWM, despite retaining myelin, often exhibits axonal swelling, activated major histocompatibility complex II 1 microglia and macrophages, gliosis, increased expression of proteolytic enzymes, and diffuse vessel leakage. [39] [40] [41] DCE-MRI has the additional advantage of using a lower dose of gadolinium contrast compared to conventional contrast MRI. Subjects with loss of NEDA at 2 years had significantly more relapses in the year preceding treatment initiation. However, baseline ARR and lesion count are not significant in the regression analysis of K i on NEDA; there is no correlation between 6-month K i and days since last relapse or baseline contrast-enhancing lesion count; we only observed 1 relapse in close proximity to the 6-month scan. This dispels the possibility that the predictive effect of the higher K i at 6 months on 2-year NEDA is a throwback to higher baseline disease activity.
Possible Reasons for Treatment Failure
We found that K i > 0.136ml/100g/min predicts suboptimal natalizumab or fingolimod treatment response with a sensitivity of 73% and specificity of 81%. Possible reasons for treatment failure include: (1) lack of compliance, (2) neutralizing antibodies, (3) uncoupling of the disease process from the drug's mechanism of action, and (4) high intrinsic disease activity. Lack of compliance and neutralizing antibodies were excluded in this study, because patients were monitored for both. Uncoupling of disease and drug mechanism of action may occur if the inflammatory process is self-driven within the brain or alternative pathways have developed that allow persistent encephalitogenic leucocyte entry into the brain, for instance, higher expression of human leucocyte antigen I, chemokines, and selectin ligands at the BBB and/or structurally damaged endothelium. When treatment failure is due to high intrinsic disease activity, the drug is effective at its target but the individual's disease is so active that the therapeutic effect is not enough and disease activity breaks through.
K i Response
In our general linear model, we find a trend toward an interaction effect of time and baseline methylprednisolone treatment, indicating a treatment effect between paired baseline and 6-month K i only if baseline methylprednisolone is accounted for. This is indicative of a cumulative "K i response" to both types of treatment, that is, a decrease in K i at baseline due to methylprednisolone and a decrease in K i during the course of treatment with fingolimod or natalizumab. Taken together, this indicates that K i response may provide a measure of treatment response. To further elucidate this relationship, one would need to follow individual patients over the course of several treatment regimes, encompassing both suboptimal and optimal treatment responses in the same individuals.
Proportion of NEDA In this study, the proportion of subjects with loss of NEDA status was 34% during the first year and 43% during the second year. One natalizumab study reported loss of NEDA status at 2 years in 38% of subjects, but that study used less stringent MRI criteria not including enlarging T2 lesions. 42 In the AFFIRM trial, 63% had lost NEDA status after 2 years of natalizumab treatment, using the same NEDA criteria as in our study. 19 A headto-head comparison of NEDA in natalizumab versus fingolimod treatment showed loss of NEDA status at 2 years in 30% and 77%, respectively. 43 The large discrepancy in the proportion of subjects with loss of NEDA status could likely represent differences in patient selection. In clinical trials, subjects with highly active disease are often favored for inclusion, to show maximum effect of the treatment, whereas in this study we included all patients starting on natalizumab or fingolimod treatment during the given time window.
Permeability Changes in the Context of Natalizumab or Fingolimod Treatment Soon et al investigated T1-weighted signal intensity changes after gadolinium-diethylenetriamine penta-acetic acid administration in 27 RRMS patients after 24 weeks on natalizumab treatment but found no effect of treatment on signal change in NAWM when compared to 13 patients receiving placebo. 44 No clinical parameters, such as recent methylprednisolone treatment, relapses, and individual treatment effect, were taken into account; these are variables that we have shown govern K i . This emphasizes the importance of including clinical covariates when characterizing changes in K i over time. Solute permeability across the BBB, which is mainly governed by diffusion, 45, 46 is not synonymous with T-cell migration across the BBB, which is a highly regulated receptor-mediated process. To assess BBB permeability in this study, we used a macrocyclic gadolinium chelate (gadobutrol; Gd-BT-DO3A), which is a 547Da highly hydrophilic molecule. 47 Thus, even though natalizumab blockage of the VLA-4 receptor results in reduced migration of T-cells across the BBB, this does not necessarily imply a change in solute permeability per se. 45, 46, 48 The time delay observed in this study of the effect of treatment on K i , and the lack of correlation between baseline visibly contrast-enhancing lesions and K i at any time point, indicate that solute permeability in NAWM is secondarily modulated by a treatment-related reduction of low-grade inflammatory activity. In summary, we find that a single DCE-MRI at 6 months after initiation of natalizumab or fingolimod treatment provides information on the state of health of the BBB that enables reliable stratification of treatment response. Thus, DCE-MRI can enable early detection of long-term suboptimal treatment response in RRMS and a personalized medicine approach to treatment, a limitation being the long scan time (15 minutes). These results and the proposed thresholds require validation in larger studies.
